A Randomized Crossover Trial of a Pressure Relief Technology (SensAwake™) in Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea. (19th December 2017)

• Record Type: Journal Article
• Authors: Bogan, Richard K.; Wells, Charles
• Other Names: Billiard Michel M. Academic Editor.
• Is Part Of: Sleep disorders. Volume 2017(2017)
• Publication Date: 2017-12-19
• Subjects: Sleep disorders -- Periodicals; 616.8498005
• DOI: 10.1155/2017/3978073
• Languages: English
• ISSNs: 2090-3545

Abstract

Abstract : Objectives/Background . Improving adherence to CPAP devices is crucial to reduce the long-term morbidity associated with OSA. SensAwake is a unique pressure relief technology that aims to promptly reduce the pressure upon sensing irregular respiration indicative of wakefulness. The purpose of this study was to compare adherence and sleep-quality outcomes in patients treated by CPAP with and without SensAwake technology. Methods . Participants with moderate-to-severe OSA were randomized to use CPAP devices with or without SensAwake (4 weeks) before crossing over. Results . Sixty-five patients completed both arms of the trial. There were no statistically significant differences in CPAP adherence with or without SensAwake over the study period (SensAwake ON272.67 ± 17.06 versus SensAwake OFF289.09 ± 15.24 ;p = 0.180 ). SensAwake reported a significantly lower system leak, 90th percentile leak, and time spent with excessive (>60 L/min) leak. Subgroup analysis suggested a trend towards improved adherence in patients with moderate-to-severe insomnia when using SensAwake. Conclusions . Using SensAwake incurred benefit in terms of reduced leaks; however, SensAwake did not improve CPAP adherence or objective sleep quality. Further studies should investigate the accuracy of observed trends towards increased adherence using SensAwake among patients with OSA and insomnia.